UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

UroGen Pharma Ltd.NASDAQ: URGN

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI falls 42.9% from a year ago

Accumulated OCI stood at $8K at the end of Q1 FY2026, down 42.9% from a year earlier and down 57.9% from the prior quarter.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -42.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8K-57.9% QoQ
Last fiscal yearDec 2025
$19K-66.1% YoY
Year agoMar 2025
$14K-42.9% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.9%——
1 year-66.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
19K USD
Year-over-year change
-66.1%

Accumulated OCI vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's Mar 2026 Accumulated OCI of $8K is the highest of the 3 companies compared; the peer median is $0.
  • Accumulated OCI amounts to 0.0% of total assets for URGN, versus a peer median of 0.0%.
URGN Competitors Peer median
Accumulated OCI for URGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
URGNUroGen Pharma Ltd.Mar 2026$8K -42.9%—0.0%
CGONCG Oncology, Inc. Common stockSep 2026$0 ——0.0%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding URGN) $0——0.0%

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents44.36M55.41M95M171.99M110.75M
Short-term Investments44.78M44.56M41.97M64.7M9.71M
Net Receivables11.72M12.7M15.44M20.3M33.08M
Inventory4.83M4.33M5.67M9.23M16.46M
Other Current Assets1.23M11.91M11.1M9.92M16.02M
Total Current Assets114.39M128.91M169.19M276.14M186.02M
Property, Plant & Equipment (Net)3.15M3.75M2.36M3.79M9.09M
Goodwill00000
Intangible Assets00000
Long-term Investments675K04.5M5.02M177K
Tax Assets00000
Other Non-current Assets1.53M2.96M2.26M765K5.16M
Total Non-current Assets5.36M6.71M9.13M9.58M14.43M
Total Assets119.75M135.62M178.31M285.71M200.46M
Account Payables5.79M5.53M6.51M10.93M12.14M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities10.28M11.53M14.67M18.52M18.7M
Total Current Liabilities22.38M23.92M31.21M45.95M46.42M
Long-term Debt097.54M98.55M121.73M122.21M
Deferred Tax Liabilities2.84M3.02M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities85.71M98.92M112.92M125.18M131.18M
Total Non-current Liabilities88.95M201.06M212.31M248.57M259.51M
Total Liabilities111.33M224.98M243.52M294.51M305.93M
Common Stock61K63K89K115K133K
Retained Earnings(467.32M)(577.1M)(679.35M)(806.22M)(959.72M)
Accumulated OCI(25K)(107K)12K56K19K
Other Stockholders Equity00000
Minority Interest00000
Total Equity8.41M(89.36M)(65.21M)(8.8M)(105.47M)
Total Debt398K99.12M99.4M123.39M128.33M
Net Debt(43.96M)43.72M4.39M(48.6M)17.59M

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.